Presentations at 2026 ESCMID Highlight Safety and Potent Bactericidal Activity of FPI-2119

EDMONTON, Alberta — April 19, 2026. Fedora Pharmaceuticals, Inc. is presenting a full suite of preclinical findings from its lead candidate, FPI-2119, at the European Society of Clinical Microbiology and Infectious Diseases Congress (ESCMID) in Munich, Germany. Presentations are authored by Fedora and collaborators at St. Jude Children’s Research Hospital, JMI Laboratories (Part of Element), Indiana University, and Pharmacology Discovery Services (a Eurofins Discovery Partner Lab).

ESCMID presentations highlight the candidate’s activity against some of the most difficult-to-treat Gram-negative infections, including respiratory tract infections, sexually transmitted infections, and high-mortality nosocomial infections — many in the high-priority category of the WHO Bacterial Priority Pathogens List.

This puts hospital patients and the greater community at serious risk of succumbing to infections that were once easily treatable. The data being presented at ESCMID show that FPI-2119 has the potential to become a valuable tool to fight today’s infectious diseases.Karen Bush, Ph.D., Indiana University professor emerita & Scientific Advisory Board member

Fedora’s poster presentations highlight the following findings from preclinical studies of FPI-2119:

• Concentration-dependent bactericidal activity and low frequency of resistance against Pseudomonas aeruginosa (Poster 2568)
• Maintenance of activity against Escherichia coli carrying a broad range of β-lactamase genes (Poster 2580)
• Activity against resistant Campylobacter, Salmonella, Shigella, Haemophilus influenzae, and Moraxella catarrhalis (Poster 2581)
• Potency against all strains of N. gonorrhoeae, including six resistant to penicillin, tetracycline, and ciprofloxacin (Poster 2583)
• No measurable cardiotoxicity and clean off-target safety profile (Poster 2599)
• Potency comparable to or lower than cefepime against MDR P. aeruginosa, E. coli, and Klebsiella pneumoniae (Poster 2601)
• Dose-dependent reductions in bacterial burden in bladder and kidney in a complicated UTI model (Poster 2643)
• Half-life and plasma concentrations predictive of once- or twice-daily dosing in humans (Poster 2801)

Our first pipeline candidate, nacubactam, is a β-lactamase inhibitor with the potential to restore bactericidal activity to β-lactam antibiotics. FPI-2119, our second candidate, is a potent antibiotic with the potential to treat infections caused by pathogens that produce β-lactamases.Christopher Micetich, CEO & Founder, Fedora Pharmaceuticals

About FPI-2119

FPI-2119, a first-in-kind derivative of the lactivicin class, is in development for Gram-negative infections. As a non-β-lactam antibiotic it is not expected to be susceptible to β-lactamases. It has demonstrated broad activity against Pseudomonas aeruginosa, Acinetobacter baumannii, and Enterobacterales. Target indications include complicated hospital-acquired and ventilator-associated pneumonia (cHABP/cVABP), complicated urinary tract infections (cUTI), and complicated intra-abdominal infections (cIAI).